OMICS International welcomes all the attendees, speakers, sponsors and other research expertise from all over the world to theInternational conferenceon Clinical and Molecular Genetics (Clinical Genetics 2016)which is going to be held duringNovember 28-30,2016inChicago, USA.We are very much honored to invite you all to exchange and share your views and experience on theCurrent Advancements and Novel Research on Genetics at Clinical and Molecular level.
Clinical and molecular geneticsare involved in the diagnosis and management ofhereditary disorderswhich determines the safety and effectiveness ofmedications,devices,diagnostic productsandtreatment regimenswhich are intended for human use and also be used for prevention, treatment, diagnosis or for relieving symptoms of a disease. There is a rapid growth in the field of Clinical and Molecular Genetics because of the increased prevalence of infectious diseases, causative mutating organisms which led to the discovery of novel clinical and genetic testing methods. TheGenetic testingmarket sale is estimated to reach $25 billion annually by 2021 with a growth rate of 10% in the United States. The genetic testing market is believed to reach approximately $60 billion by 2020 globally. US represent the largest market for genetic testing worldwide.
Track -1:Mendelian Genetics: Past and the future
For thousands of years there were lot of questions about genetics and people followed different processes to produce hybrids of different plants and animals. But most of their trails failed as the actual mechanism behind it was unknown. ThereafterMendelwas the first to explain the concept of heredity after experimenting on pea plant (Pisum sativum)through his laws. He proposed Law of Segregation where only one allele pass from parent to offspring as the allele of parents gets separated ,Law of independent Assortment where different pairs of allele passes from parents independently, Law of Dominance where some alleles are dominant the remaining are recessive. Based on this, several hypotheses were proposed later.
Currently there are vast advancements in the field of genetics where researches are focusing on the different diseases caused by variations in genes and many institutions are investing in the research. For example, US government, along with NIH funded Human Genome project based onDNA sequencingtechnologies. Due to the development of new techniques in Bioinformatics there is a huge decrease in the price of genome sequencing, from $100 million to $1000.
The involvement of genetics in heart diseases, cancer and other implications remained far from clear. There are possibilities of practicing human cloning, eugenics apart from these genetic advancements.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-2:Clinical Genomics
Clinical genomics is the use ofgenomic sequencingin clinical basis like for diagnosis, treatment of disease caused in patients. It is a new and rapidly changing field. The diseases like cystic fibrosis and sickle cell anaemia, which are caused by a single base pair change to DNA sequencing, these mutations can be corrected by CRISPR/ Cas technology.
Cas technologyis based on genome editing which is proposed by Editas Medicine with an investment of about $43million. Researchers adopted this technique as most of the microbes use protein and RNAs against invading viruses. The technique involves the editing of stretches in DNA and also to edit single base pairs of the human genome. It was also believed to cure untreatable diseases possibly.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-3:Oncogenomics and Therapeutics
Oncogenomics is the study of the relationship between cancer and the genome of an individual. Its goal is to identifyoncogenesfor the diagnosis and treatment of cancer. Cancer is a genetic disease as it is caused by genetic variation in DNA.NIH offers about $7.4 billion on research related to genetics and about $5.8 on cancer related research. The various techniques used are DNA sequencing, microarray, digital karyotyping, bacterial artificial chromosome.
The American Cancer Society reported that among 1.5 million cases half a million die from the disease mostly of breast cancer, lung cancer, bladder cancer, leukemia. The expenditure on cancer care in 2010 was $125 billion and is estimated to reach $156 billion by 2020 in US.US occupies seventh place inbreast cancerworldwide.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track- 4:Clinical Epigenetics
Clinical epigenetics uses the techniques involved in molecular biology to detect the alterations in DNA methylation or histone modification to diagnose disorders produced by heritable defects in thegene expression. DNA methylation involves in the addition of methyl groups to adenine and guanine bases. DNA is useful for cell development and when methylation occurs on CpG dinucleotide where cytosine precedes guanine suppresses the gene regulation. The nucleosome consists of historians where the tails of histone protrude from nucleosome and therefore they can be modified. The chemical groups attract activating or suppressing complexes to chromatin, which affects its shape, making it more or less available for gene expression. Epigenetic enzyme marketing consists of DNA-modifying, RNA-modifying, Protein is modifying Enzymes which is expected to reach a high rate by 2019. Bisulfite conversion kits; ChIP- seq kits; RNA sequencing kits; whole genome amplification kits are some of the epigenetic kits among which ChIP-seq kits segment had the biggest share in 2014.The market value ofepigeneticswas $413.24 million in 2014, it is expected to reach a CAGR of 13.64% from 2014 to 2019 and it is estimated to grow $783.17 million by 2019 globally.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-5:Regenerative biology and Stem Cell research
Regenerative biology involves the restoration or renewal of damaged genes, cells, tissues, organisms or ecosystem that is produced by some natural fluctuations.Regenerationis mediated by gene regulation and it may be complete (same as old tissue) or incomplete (fibrosis). The market value for tissue engineering and regeneration products was $55.9 billion in 2010 and $59.8 billion in 2011, and is expected to reach $89.7 billion by 2016 at a CAGR of 8.4% globally. According to the reports, the market value of regenerative medicine was about $2.5 billion in the US.
Stem cells are undifferentiated biological cells that undergo mitosis to produce more cells, which are found in multicellular organisms. They are of two types, embryonic and adult stem cells. The stem cell treatment was found to be a lifesaving treatment for the patients with solid tumors and blood disorders.Stem cellscan be obtained from the umbilical cord after babys birth. Possibly they can also be obtained from peripheral blood and bone marrow. According to the reports, in US the availability of stem cell therapy was $15.2 million in 2007 and $16.5 million in 2008 and it is estimated to reach $11 billion by 2020.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-6:Microbial and Human Genetics
There are millions of microorganisms that have a rapid impact on our health. They play a vital role in maintaining the health as well as in the onset of diseases.
Genomics applies DNA sequencing methods andBioinformaticsto analyze the structure and function of genomes. It started from bacteriophage but was overtaken by bacterial genomics. Its applications were included in the fields of medicine, biotechnology and social sciences.
Proteomics is the study of the structure and functions of proteins as they are the essential components of the various metabolic pathways of cells. It is more complicated when compared to genomic studies as it varies from cell to cell.Mass spectroscopyand microarray techniques are mostly used to study proteins presently.
The global market for DNA sequencing products and services in 2012 was $3.5 billion and $4.5 billion in 2013. It is expected to reach $11.7 billion by 2018 with a CAGR of 21.2%.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-7:Next Generation Sequencing
Next Generation Sequencing is a novel method for sequencing DNA and RNA more rapidly, which has made the study of genomics easy. It is the most versatile tool for medical and biological research. The techniques involved are Illumina sequencing, Roche 454 sequencing, Ion torrent: proton sequencing,Solid sequencing. Illumina sequencing is based on DNA colonies or clusters that involves in the clonal amplification of DNA on a surface.454 pyro sequencing amplifies DNA in side water droplets in an oily solution. Ion torrent sequencing is based on using sequencing chemistry with semiconductor based detection system. It is based on detection of hydrogen ions used during polymerisation of DNA whereas solid sequencing involves sequencing by ligation. The NGS market reached $231.7 million in 2012 and $510.7 million in 2013 and is expected to reach $7.6 billion by 2018 with a CAGR of 71.6% globally.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-8:Clinical metabolics and Lipidomics
Lipids are the major components of biological membranes as well as the metabolites of organisms. Lipids play crucial role in biology. Imbalance in the lipid molecules leads to numerous diseases like atherosclerosis, obesity, diabetes, andAlzheimer's disease. Lipidomics is a system-based study of all lipids, which aims at the analysis of lipids in the biological system. Lipidomics is the main tool for potential biomarker discovery, diagnosis the disease and to understand disease pathology mainly in the fields of neurodegeneration, psychiatry, oncology, metabolic diseases, and infectious diseases. The global biomarkers market was $29.3 billion in 2013 and is expected to grow $53.6 billion in 2018 at a CAGR of 12.8%.
Clinical metabolomics is the major and the most powerful tool to screen metabolites in the biological samples. These provide predictive and prognostic biomarkers which are useful to monitor disease states and to improve therapeutic levels. Discovery of biomarkers to differentiate diseases at molecular levels is a difficult task as the metabolite profile is related to the phenotype of an organism;metabolomicsprovide a better understanding of systemic diseases. Metabolomics is also practiced in crop breeding, toxicology, plant biotechnology. The market value for metabolomics was $712 million in 2012 and is expected to reach nearly $1.4 billion in 2017 at a CAGR of 14.2% globally.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-9:Medical and Developmental genetics
Right from the zygote to a developed individual every process is regulated by genes. Developmental genetics is concerned with the process in which genes regulate the development. It is the study of cell fate, cell determination and embryonic development. There are many theories proposed and among them differential gene expression is the most accepted one. The ability to produce an organism from cells is called totipotent, unipotent stem cells produce a family of related cells. Pluripotent and multipoint produce only few organs or tissues, but all these cells forms, acell lineagewhose differentiation can be done by a master control gene. Likewise immune cells are produced from bone marrow; B-cells are responsible for antibody production. By Invivo production of B-cells, antibody diversity can be achieved as process follows differential gene expression. The prenatal and newborngenetic testingmarket were $1.12 billionin 2012 and expected to grow $8.37 billionin 2019 at a CAGR of 26.9% from 2013 to 2019 globally.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-10:Genetic Syndromes and Related Disorders
Genetic disorder is a genetic problem which is associated with the abnormalities in the genome, it may or may not be heritable. For example, cancer can be caused by some inherited genes or by newmutationsor it may be environmental cause in some patients. There are many genetic disorders among them Single-gene disorder is the one which is the resultant of a single mutated gene. It includes diseases like Cystic fibrosis,Sickle-cell-anemia, Polycystic kidney disease, Hemophilia-A, Albinism. Multifactorial diseases include diabetes and heart diseases. Most of the genetic disorders can be identified at birth or in childhood like Huntingtons disease. Treatment for these genetic disorders is still a battle where around 1800 clinical trials have been completed. Presently Gene therapy is followed in which a new gene is introduced to a patient which is very complicated. The market value of products to treatgenetic disorderswas $12.8 billion in 2009 and $17.3 in 2014 globally.
The market value for cancer treatment was about $51.2 billion in 2014 and is expected to reach $66.4 billion by 2019, with a CAGR of 5.4% from 2014 to 2019 globally.The autism spectrum disorders(ASD) market was about $346.2 million in 2013 and $360.9 million in 2014. The market value is expected to grow to $412.7 million by 2019, with a CAGR of 2.7 %.
Related Conferences:
World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Track-11: Genetics Market:
While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future. Many expressed opinions that genetic services will make significant contributions to prediction, detection, and care selection, leading to better quality care and increased affordability. Available genetic tests and genomic applications, can be categorized according to their clinical method of use across prediction, detection, and care selection. The prenatal and newborngenetic testingmarket were $1.12 billionin 2012 and expected to grow $8.37 billionin 2019 at a CAGR of 26.9% from 2013 to 2019 globally.
Related Conferences:
World congress onHuman Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling andGenomicsMedicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility andImmunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics &Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference onCancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China;DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America
Cell Therapy-2015
OMICS International Conferencessuccessfully hosted its premier4thInternational Conference and Exhibition on Cell & Gene Therapyduring August 10-12, 2015 at Crowne Plaza London-Heathrow, London, United Kingdom.
The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.
Cell Therapy-2015is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.
OMICS InternationalConferenceswishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partnersfor their promotion to make this event a huge success.
This4thInternational Conference and Exhibition on Cell & Gene Therapybased on the themeGenomic therapies from base pairs to bedsidewhich covered the below scientific sessions like Cell and Gene Therapy: Potential Applications, Plant Stem Cell Rejuvenation, Plant Stem Cells: Human Therapeutics, Stem Cell Therapies, Cellular Therapies, Advanced Gene Therapeutics, Molecular basis of epigenetics, Cancer Therapies, Nano-Therapy, Bioengineering Therapeutics, Clinical Trials and Research in Cell and Gene Therapies, Regulatory and Ethical Issues of Therapies.
The conference was greeted by the conference Moderator:Dr. Andrei Laikhter,Chemgenes Corporation, USA. The support was extended by the Keynote Speaker:Dr. James Koropatnic,Lawson Health Research Institute and Western University;Dr. Anelia Atanassova,BioGlobaX Inc., Canada;Dr. Noriyuki Kasahara,University of Miami, USA;Dr. Robert Hawkins,The Christie Hospital and University of Manchester, UK andDr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA
OMICSInternationalacknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included:Dr. Ajan Reginald,Cell Therapy Limited, UK;Dr. Andrei Laikhter,Chemgenes Corporation, USA;Dr. Vasiliki Kalodimou,IASO Maternity Hospital, Greece;Dr. Geeta Shroff,Nutech Medicworld, India;Dr. Nady Golestaneh,Georgetown University School of Medicine, USA;Dr. James Koropatnick,Lawson Health Research Institute and Western University, Canada;Dr. Robert Hawkins,Christie Hospital and University of Manchester, UK.
This4thInternational Conference and Exhibition on Cell & Gene Therapywas uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2015 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event.
With the enormous feedback from the participants and supporters 4thInternational Conference and Exhibition on Cell & Gene Therapy,OMICS International Conferencesis glad to announce its5thInternational Conference and Exhibition on Cell & Gene Therapy(Cell Therapy-2016) event from May 19-21, 2016 at San Antonio, USA
- See more at: http://cellgenetherapy.conferenceseries.com/#sthash.npJGo7Qv.dpuf
OMICS International Conferencessuccessfully hosted its premier4thInternational Conference and Exhibition on Cell & Gene Therapyduring August 10-12, 2015 at Crowne Plaza London-Heathrow, London, United Kingdom.
The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.
Cell Therapy-2015is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.
OMICS InternationalConferenceswishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partnersfor their promotion to make this event a huge success.
This4thInternational Conference and Exhibition on Cell & Gene Therapybased on the themeGenomic therapies from base pairs to bedsidewhich covered the below scientific sessions like Cell and Gene Therapy: Potential Applications, Plant Stem Cell Rejuvenation, Plant Stem Cells: Human Therapeutics, Stem Cell Therapies, Cellular Therapies, Advanced Gene Therapeutics, Molecular basis of epigenetics, Cancer Therapies, Nano-Therapy, Bioengineering Therapeutics, Clinical Trials and Research in Cell and Gene Therapies, Regulatory and Ethical Issues of Therapies.
The conference was greeted by the conference Moderator:Dr. Andrei Laikhter,Chemgenes Corporation, USA. The support was extended by the Keynote Speaker:Dr. James Koropatnic,Lawson Health Research Institute and Western University;Dr. Anelia Atanassova,BioGlobaX Inc., Canada;Dr. Noriyuki Kasahara,University of Miami, USA;Dr. Robert Hawkins,The Christie Hospital and University of Manchester, UK andDr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA
OMICSInternationalacknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included:Dr. Ajan Reginald,Cell Therapy Limited, UK;Dr. Andrei Laikhter,Chemgenes Corporation, USA;Dr. Vasiliki Kalodimou,IASO Maternity Hospital, Greece;Dr. Geeta Shroff,Nutech Medicworld, India;Dr. Nady Golestaneh,Georgetown University School of Medicine, USA;Dr. James Koropatnick,Lawson Health Research Institute and Western University, Canada;Dr. Robert Hawkins,Christie Hospital and University of Manchester, UK.
This4thInternational Conference and Exhibition on Cell & Gene Therapywas uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2015 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event.
With the enormous feedback from the participants and supporters 4thInternational Conference and Exhibition on Cell & Gene Therapy,OMICS International Conferencesis glad to announce its5thInternational Conference and Exhibition on Cell & Gene Therapy(Cell Therapy-2016) event from May 19-21, 2016 at San Antonio, USA
Cell Therapy-2014
3rdInternationalConferenceand Exhibition on Cell & Gene Therapywas held duringOctober 27-29, 2014 at Las Vegas, USAwith a theme Uncover the potential that lies within the cell brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue ofJournal of Stem Cell Research & Therapy.
Cell Therapy-2014opened up new vistas and fostered collaborations in the industry and academia.
The conference was embarked with an opening ceremony followed by a series of lectures delivered by bothHonorable Guestsand members of theKeynote forum. The adepts who promulgated the theme with their exquisite talk were;
Dr. Paul L Hermonat,Central Arkansas Veterans Healthcare System, USA Dr. Peter J Quesenberry, The Warren Alpert Medical School of Brown University, USA Dr. Rafael Gonzalez,DaVinci Biosciences, LLC USA Dr. Paul J Davis, Albany Medical College, USA Dr. Stephen Lin,Thermo Fisher Scientifi c, USA
OMICS Grouphas taken the privilege of felicitatingCell Therapy-2014Organizing Committee, Editorial Board Members, Keynote Speakers and business delegates who supported for the success of this event.
OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Cell & Gene and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.Our warm gratitude to our sponsors exhibitors & media partners for associating with the conference.
Cell Therapy-2013
2ndInternationalConferenceand Exhibition on Cell & Gene Therapywas held duringOctober 23-25 2013,atOrlando-FL, USAwith a theme Innovative Strategies in Cell & Gene Therapies brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue ofJournal of Stem Cell Research & Therapy.
Cell Therapy-2013opened up new vistas and fostered collaborations in the industry and academia.
Excerpt from:
International Conference on Clinical and Molecular Genetics